Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease
Authors:
- Raed Al-DabbaghRARaed Al-Dabbagh
- Amit DhillonADAmit Dhillon
- Bruce E. SandsBSBruce E. Sands
- John K. MarshallJMJohn K. Marshall
- 1 October 2014
- journal article
- review article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 20 (10) , 1862-1869
Abstract
The use of TNFα antagonists is well described for inflammatory bowel disease (IBD), but their safety profile during pregnancy is yet to be fully elucidated. A systematic review and meta-analysis were performed to identify studies that explored the safety of anti-TNFα therapy during pregnancy in patients with IBD. A systematic literature search was conducted to identify studies that investigated the pregnancy outcomes among women with IBD on anti-TNFα therapy. The primary outcome was the overall rate of unfavourable pregnancy-related outcomes among women with IBD on anti-TNFα therapy. Secondary outcomes included rates of abortions (spontaneous or elective), preterm delivery, low birth weight, and congenital malformations. Odds ratios (OR) with 95% confidence interval (CI) are reported. Eligible studies used an observational or interventional design, enrolled subjects with IBD on anti-TNFα therapy for at least 1 trimester and compared outcomes with appropriately matched controls. Overall, 5 studies with a total of 1216 participants were eligible for inclusion in the meta-analysis. There was no significant difference in the rates of total unfavourable pregnancy outcomes between pregnant women with IBD who were on anti-TNFα therapy and controls not on anti-TNFα therapy (OR, 1.00 [95% CI, 0.72-1.41]). Similarly, there were no statistically significant differences in the rates of abortion (OR, 1.53 [95% CI, 0.97-2.41]), preterm birth (OR, 1.00 [95% CI, 0.62-1.62]), low birth weight (OR, 1.05 [95% CI, 0.62-1.78]), or congenital malformation (OR, 1.10 [95% CI, 0.58-2.09]). The use of anti-TNFα therapy does not seem to increase the risk of unfavorable pregnancy outcomes among women with IBD, although the optimal timing of therapy through pregnancy and the postpartum period was not assessed in this analysis. These data can help counsel patients around family planning and perinatal management.Keywords
This publication has 26 references indexed in Scilit:
- Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center studyScandinavian Journal of Gastroenterology, 2013
- Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2013
- Effects of Discontinuing Anti–Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal ExposureClinical Gastroenterology and Hepatology, 2013
- Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyInflammatory Bowel Diseases, 2011
- Safety of infliximab use during pregnancyReproductive Toxicology, 2011
- Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feedingInflammatory Bowel Diseases, 2010
- A meta-analysis on the influence of inflammatory bowel disease on pregnancyGut, 2006
- Pregnancy outcome in women who were exposed to anti–tumor necrosis factor agents: Results from a national population registerArthritis & Rheumatism, 2006
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisAmerican Journal of Gastroenterology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003